Kenvue (US:KVUE) Fastcompanyยท2025-09-22 20:40Core Viewpoint - Kenvue Inc. (KVUE), the parent company of Tylenol, is experiencing a decline in stock price due to concerns raised by the Trump administration linking Tylenol to autism risk, despite existing studies refuting this claim [2][5][6]. Company Overview - Kenvue was spun off from Johnson & Johnson in 2023 and is known for various household products, including Tylenol, Band-Aid, Listerine, and Zyrtec [3]. - Tylenol, containing acetaminophen, has been available over-the-counter in the U.S. since 1960 and is widely used for pain relief and fever reduction [4]. Industry Concerns - Federal health officials are expected to announce concerns regarding the use of acetaminophen by pregnant women, citing research suggesting a potential link to autism [5]. - The CDC reported that the diagnosis rate of autism in American 8-year-olds has increased from one in 150 in 2000 to one in 31 in 2022, highlighting a growing public health concern [8]. Response from Kenvue - Kenvue has stated that acetaminophen does not cause autism, aiming to clarify the safety of their product amidst rising concerns [8].